Overview
Esophageal cancer is one of the most common cancers in China and a major cause of cancer mortality across Asia. For patients seeking the most advanced surgical treatment — including robotic minimally invasive esophagectomy, organ-preservation strategies, and cutting-edge neoadjuvant immunotherapy — Shanghai's Chest Hospital is home to the world's leading esophageal cancer surgical program.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top esophageal cancer specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Esophageal Cancer
What Is Esophageal Cancer?
Esophageal cancer develops in the lining of the esophagus — the muscular tube connecting the throat to the stomach. There are two main types:
- Squamous cell carcinoma (SCC) — the predominant type in Asia, arising from the squamous cells lining the esophagus; strongly associated with smoking and alcohol use
- Adenocarcinoma — more common in Western countries; associated with gastroesophageal reflux disease (GERD) and Barrett's esophagus
China accounts for approximately 50% of global esophageal cancer cases, driving the development of exceptional surgical expertise and innovative treatment protocols at Shanghai's leading thoracic centers.
Common Symptoms
- Progressive difficulty swallowing (dysphagia) — first with solids, then liquids
- Unexplained weight loss
- Chest pain, pressure, or burning
- Hoarseness or chronic cough
- Regurgitation of food
- Fatigue and anaemia
Risk Factors
- Smoking and heavy alcohol use (particularly for SCC)
- Gastroesophageal reflux disease (GERD) and Barrett's esophagus (for adenocarcinoma)
- Hot beverage consumption
- Low fruit and vegetable intake
- Obesity (for adenocarcinoma)
- Family history of esophageal cancer
Diagnosis & Staging
- Upper endoscopy (gastroscopy) with biopsy — definitive diagnosis and histological subtyping
- CT scan (chest/abdomen/pelvis) — locoregional and distant staging
- Endoscopic ultrasound (EUS) — T and N staging, critical for surgical planning
- PET-CT — detection of occult metastasis and nodal disease
- Bronchoscopy — for mid-esophageal tumors to assess airway involvement
- Molecular profiling — HER2, PD-L1, MSI/MMR for targeted and immunotherapy eligibility
Treatment Options for Esophageal Cancer
Surgery: Esophagectomy
Surgical resection (esophagectomy) remains the cornerstone of curative treatment for resectable esophageal cancer. The main approaches include:
- Minimally invasive esophagectomy (MIE) — laparoscopic and thoracoscopic approach; the current standard at leading centers
- Robotic-assisted minimally invasive esophagectomy (RAMIE) — the most advanced approach, offering enhanced precision, better visualization, and improved lymph node dissection
- Ivor Lewis esophagectomy — combined abdominal and right thoracic approach
- McKeown (three-field) esophagectomy — for upper esophageal tumors requiring cervical anastomosis
Robotic-Assisted Esophagectomy: The Global Frontier
Robotic-assisted minimally invasive esophagectomy (RAMIE) represents the current frontier of esophageal cancer surgery. Compared to conventional thoracoscopic surgery, robotic assistance provides:
- Enhanced 3D visualization and 10x magnification
- Greater instrument precision and range of motion in the confined thoracic space
- Improved lymph node dissection — associated with better oncological outcomes
- Reduced blood loss and lower complication rates
- Faster recovery and shorter hospital stay
The landmark ROBOT trial — the world's first multicenter randomized controlled trial comparing robotic versus conventional thoracoscopic esophagectomy — was led by Prof. Li Zhigang and published in Annals of Surgery, providing the highest level of evidence for the superiority of robotic esophagectomy.
Neoadjuvant Immunotherapy: The NICE Study
One of the most significant recent advances in esophageal cancer treatment is the integration of immune checkpoint inhibitors (ICIs) into the preoperative (neoadjuvant) setting. The NICE study — China's first prospective study of neoadjuvant immunotherapy for esophageal cancer, led by Prof. Li Zhigang — demonstrated that adding PD-1 inhibitors to neoadjuvant chemotherapy significantly improves pathological response rates before surgery. The results have been published in top-tier international journals and incorporated into national treatment guidelines.
Organ Preservation: Avoiding Surgery When Possible
For patients who achieve an exceptional response to neoadjuvant chemoimmunotherapy — with near-complete or complete tumor regression — an organ preservation strategy may be considered: intensive surveillance instead of immediate surgery, preserving the esophagus and avoiding the morbidity of esophagectomy while maintaining oncological safety. This approach requires precise response assessment and is offered selectively at specialist centers with the expertise to identify appropriate candidates.
Systemic Therapy
- Neoadjuvant chemoradiotherapy (nCRT) — standard for locally advanced esophageal cancer before surgery (CROSS regimen)
- Neoadjuvant chemotherapy + immunotherapy — emerging standard, particularly for SCC
- Adjuvant immunotherapy — nivolumab after nCRT + surgery for residual disease (CheckMate 577)
- Palliative systemic therapy — chemotherapy + immunotherapy for advanced/metastatic disease
Why Choose Shanghai for Esophageal Cancer Treatment?
- World's #1 robotic esophageal cancer surgery center — Shanghai Chest Hospital has performed over 1,700 robotic esophagectomies — the highest single-center volume globally
- Pioneer of neoadjuvant immunotherapy — the NICE study results are now incorporated into national guidelines
- Organ preservation expertise — selective non-surgical management for exceptional responders
- International guideline leadership — Prof. Li led the first international expert consensus on robotic esophageal cancer surgery
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Li Zhigang — Shanghai Chest Hospital
Prof. Li Zhigang (李志刚) is one of China's foremost esophageal cancer surgeons and a global leader in robotic thoracic surgery, based at Shanghai Chest Hospital — China's premier dedicated thoracic disease center.
International Leadership
- Vice President of the International Society for Diseases of the Esophagus (ISDE) — the highest international leadership role in esophageal disease held by a Chinese surgeon
- State Council Special Government Allowance — China's highest honor for outstanding contributions to science and technology
- "Shanghai Craftsman" and "Shanghai Good Doctor" — municipal recognition for surgical excellence and patient care
World Records in Robotic Esophageal Surgery
- Over 1,700 robotic-assisted esophagectomies — the highest single-center volume in the world
- Lead author of the first international expert consensus on robotic esophageal cancer surgery — setting the global standard for this technique
- Principal investigator of the ROBOT trial — the world's first multicenter RCT of robotic vs. thoracoscopic esophagectomy, published in Annals of Surgery
Clinical Innovation
- NICE study — China's first neoadjuvant immunotherapy study for esophageal cancer; results published in top journals and incorporated into national guidelines
- Organ preservation strategy — pioneering selective non-surgical management for exceptional responders to neoadjuvant therapy
- 8,000+ specialist esophageal surgeries — cumulative departmental volume at Shanghai Chest Hospital's esophageal disease center
Clinical Expertise
- Robotic-assisted minimally invasive esophagectomy (RAMIE) — world's highest-volume robotic esophageal surgeon
- Neoadjuvant immunotherapy + surgery — integrated chemoimmunotherapy and surgical planning
- Organ preservation for exceptional responders — precise response assessment and surveillance protocols
- Complex and difficult esophageal disease — leading national center for challenging esophageal cases
For international patients, Prof. Li's team offers remote pre-consultation review of endoscopy reports, CT scans, PET-CT, and pathology, enabling a precise staging assessment and individualized treatment plan to be developed before arrival in Shanghai.
Clinic schedule (for reference): Expert clinic — Tuesday mornings; Special needs clinic — Tuesday afternoons. Please confirm the latest schedule through Shanghai Chest Hospital's official app or phone before traveling.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Li Zhigang and the Shanghai Chest Hospital esophageal cancer team
- ✅ Endoscopy, CT, PET-CT, and pathology translation and pre-consultation review
- ✅ Second opinion facilitation
- ✅ Hospital admission and surgical scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with esophageal cancer and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0 comentarios